Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1119 Results

Title
Intervention Indication Therapeutic Area Year Actions
Tafamidis for Transthyretin Amyloid Cardiomyopathy Tafamidis meglumine (Vyndaqel; Fx-1006A; PF-06291826) Transthyretin amyloid cardiomyopathy Cardiovascular System 2018 View  |  Download
Tafasitamab in combination with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma Tafasitamab (MOR208; Monjuvi) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Tafasitamab with lenalidomide as add-on therapy for previously treated follicular lymphoma or marginal zone lymphoma Lenalidomide (Revlimid) , Tafasitamab (MOR208; Monjuvi) Follicular lymphoma , Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2023 View  |  Download
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm Tagraxofusp (Elzonris; SL-401) Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Haematological Cancer and Lymphomas 2018 View  |  Download
Talazoparib in addition to enzalutamide for metastatic castration-resistant prostate cancer Enzalutamide (Xtandi; MDV3100) , Talazoparib (MDV3800; BMN-673; Talzenna; talazoparib tosylate) Prostate cancer Male Reproductive Cancer 2021 View  |  Download
Talimogene laherparepvec in addition to pembrolizumab for metastatic melanoma Pembrolizumab (Keytruda; MK-3475) , Talimogene laherparepvec (Imlygic; T-Vec) Melanoma Skin Cancer 2020 View  |  Download
Talquetamab for previously treated relapsed or refractory multiple myeloma Talquetamab Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Tanezumab for cancer pain due to bone metastasis Tanezumab (PF-04383119; RN624) Cancer pain Bone and Cartilage Cancer , Oncology 2020 View  |  Download
Tanezumab for moderate to severe chronic pain associated with osteoarthritis and chronic low back pain Tanezumab (PF-04383119; RN624) Back pain , Osteoarthritic pain Musculoskeletal System , Pain Relief , Rheumatology 2019 View  |  Download
Tarlatamab for relapsed/refractory small-cell lung cancer Tarlatamab Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2023 View  |  Download
1 2 94 95 96 97 98 111 112
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications